Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL^pro targeting repurposed drug candidates.

ABSTRACT:

Background

Severe acute respiratory syndrome (SARS) has been initiating pandemics since the beginning of the century. In December 2019, the world was hit again by a devastating SARS episode that has so far infected almost four million individuals worldwide, with over 200,000 fatalities having already occurred by mid-April 2020, and the infection rate continues to grow exponentially. SARS coronavirus 2 (SARS-CoV-2) is a single stranded RNA pathogen which is characterised by a high mutation rate. It is vital to explore the mutagenic capability of the viral genome that enables SARS-CoV-2 to rapidly jump from one host immunity to another and adapt to the genetic pool of local populations.

Methods

For this study, we analysed 2301 complete viral sequences reported from SARS-CoV-2

SUBMITTER: Chitranshi N 

PROVIDER: S-EPMC7344048 | biostudies-literature | 2020 Jul

REPOSITORIES: biostudies-literature